Training activity information
Details
Interpret the analyses to laboratory standard operating procedures on patients with endocrine causes of obesity, including:
- Hypothyroidism,
- Type 2 diabetes,
- Cushing’s syndrome
- Growth hormone deficiency
Type
Entrustable training activity (ETA)
Evidence requirements
Evidence the activity has been undertaken by the trainee repeatedly, consistently, and effectively over time, in a range of situations. This may include occasions where the trainee has not successfully achieved the outcome of the activity themselves. For example, because it was not appropriate to undertake the task in the circumstances or the trainees recognised their own limitations and sought help or advice to ensure the activity reached an appropriate conclusion.
Reflection at multiple timepoints on the trainee learning journey for this activity.
Reflective practice guidance
The guidance below is provided to support reflection at different time points, providing you with questions to aid you to reflect for this training activity. They are provided for guidance and should not be considered as a mandatory checklist. Trainees should not be expected to provide answers to each of the guidance questions listed.
Before action
What does success look like?
- Identify what is expected of you in relation to effectively interpreting analyses for conditions that can cause obesity (Hypothyroidism, Type 2 diabetes, Cushing’s syndrome, Growth hormone deficiency) according to laboratory SOPs.
- Consider how the learning outcomes apply, specifically in relation to performing clinical and laboratory investigation, analysis and management of endocrine disorders and diabetes mellitus.
- Discuss with your training officer to gain clarity of what is expected of you in relation to key considerations for interpreting results in patients where obesity is a presenting feature or contributing factor, especially when assessing borderline results.
What is your prior experience of this activity?
- Think about what you already know aboutnterpreting analyses for thyroid function, glucose/diabetes markers (e.g., HbA1c), cortisol (e.g., LDDST), and growth hormone (e.g., IGF-1).
- Consider possible challenges you might face during the activity, such as interpreting results in the context of obesity itself (which can affect some axes), differentiating between primary and secondary causes (e.g., hypo/hypercortisolism), or understanding the interplay of these conditions.
- Recognise the scope of your own practice for this activity i.e. know when you will need to seek advice or help, and from whom. You will need to seek advice from your Training Officer when required, for example when interpreting cortisol results in a severely obese patient, as specific tests for Cushing’s Syndrome (e.g., urinary free cortisol) may require careful interpretation due to potential confounding factors.
- Acknowledge how you feel about embarking on interpreting analyses related to endocrine causes of obesity.
What do you anticipate you will learn from the experience?
- Consider the specific skills you want to develop, such as analysing and interpreting results for these conditions in the context of obesity and selecting appropriate screening tests based on patient presentation.
- Identify the specific insights you hope to gain into how obesity might impact these endocrine axes (e.g., insulin resistance) or the interpretation of results, and the diagnostic flow for evaluating endocrine causes of obesity.
What additional considerations do you need to make?
- Consult actions identified following previous experiences of these specific endocrine tests or with interpreting results in complex patient populations where co-morbidities influenced the outcome.
- Identify important information you need to consider before embarking on the activity, such as understanding of the physiological links between obesity and these endocrine conditions, and specific testing protocols (e.g., overnight dexamethasone suppression test protocols).
In action
Is anything unexpected occurring?
- Are you noticing anything surprising or different from what you anticipate whilst performing the analysis or interpreting results for endocrine causes of obesity?
- Are you encountering situations such as:
- Borderline results for cortisol or thyroid function that are difficult to definitively link to Cushing’s syndrome or Hypothyroidism?
- Difficulties interpreting Growth Hormone deficiency markers (IGF-1) in an obese patient?
- Suspecting the influence of obesity itself on hormone levels, complicating interpretation?
How are you reacting to the unexpected development?
- How is this impacting your actions? For example, are you responding to the situation appropriately? Are you adapting or changing your approach to verifying results or interpreting complex profiles?
- Consider the steps you are taking in the moment, such as:
- Immediately cross-referencing IGF-1 results with age-matched reference ranges for suspected GH deficiency
- Consulting the Training Officer about the appropriate follow-up test when initial screening results for Cushing’s syndrome are equivocal
- Reviewing literature on the impact of Type 2 diabetes medications on specific analytical markers
- How are you feeling in that moment? For instance, are you finding it difficult to differentiate clinical disease from physiological changes due to obesity? Is it affecting your confidence in selecting the appropriate follow-up tests?
What is the conclusion or outcome?
- Identify how you are working within your scope of practice. For example, are you successfully identifying a clear profile consistent with primary hypothyroidism? Or are you needing support because the interpretation of a dynamic test for Cushing’s syndrome is ambiguous and requires senior consultant review?
- What are you learning as a result of the unexpected development? For example, are you mastering the systematic investigation flow for endocrine causes of obesity? Or gaining insight into how co-morbidities like obesity influence hormone metabolism?
On action
What happened?
- Begin by summarising the key steps you took when performing and interpreting the analyses relevant to endocrine causes of obesity (e.g., low dose Dexamethasone Suppression Test for Cushing’s Syndrome).
- Consider specific events, actions, or interactions which felt important, such as noting the patient’s obesity or diabetes status when reviewing cortisol or TSH results or observing borderline results that complicated the interpretation.
- Include any ‘reflect-in-action’ moments where you had to adapt to the situation as it unfolded, for instance, immediately consulting literature to confirm the influence of obesity on IGF-1 measurement.
- How did you feel during this experience, e.g., did you feel focused on differentiating between pathological causes and physiological effects or challenged by interpreting borderline Cushing’s screening tests?
How has this experience contributed to your developing practice?
- Identify what learning you can take from this experience regarding investigating endocrine causes of obesity. What strengths did you demonstrate, e.g., accurate application of standard interpretation guidelines?
- What skills and/or knowledge gaps were evident, e.g., unfamiliarity with the limitations of using specific dynamic tests in the context of severe obesity?
- Compare this experience against previous engagement with similar activities – were any previously identified actions for development achieved? Has your practice improved in applying standard interpretation guidelines within the context of co-morbid obesity?
- Identify any challenges you experienced, such as needing to seek advice or clarification on scope of practice regarding whether to proceed with further tests when initial screening (e.g., for hypothyroidism) was ambiguous, and how you reacted to this.
What will you take from the experience moving forward?
- Identify the actions or ‘next steps’ you will now take to support the assimilation of what you have learnt, including from any feedback you have received, with regards to interpreting specific tests in patients presenting with obesity.
- What will you do differently next time you approach investigating potential endocrine causes of obesity, for instance, by proactively reviewing the specific diagnostic pathways for Cushing’s Syndrome?
- Do you need to practise any aspect of the activity further, such as applying standard interpretation guidelines within the context of co-morbid obesity or key learning outcomes related to understanding the limitations of screening tests in this population?
Beyond action
Have you revisited the experiences?
- How have your subsequent experiences of interpreting results related to metabolic health since completing this specific training activity led you to revisit your initial approach or decisions during that activity? For example, how an instance where a subsequent severely obese patient required screening for Cushing’s syndrome (e.g., low-dose DST or urinary cortisol) forced you to re-evaluate the influence of obesity itself on borderline hormone levels you encountered during your first attempt at interpretation?
- Considering what you understand about the interplay between endocrine disorders, metabolic health, and the limitations of screening tests in obesity now, were the actions or considerations you identified after your initial reflection on this training activity sufficient? How have you since implemented or adapted improvements in your screening interpretation process for endocrine causes of obesity based on further learning and experiences? For example, how you proactively reviewed and integrated guidelines for interpreting IGF-1 (Growth Hormone deficiency marker) in adults with weight issues, demonstrating you have adapted improvements based on further learning?
- Has discussing equivocal screening test results or the influence of type 2 diabetes treatment on other endocrine axes with colleagues, peers, or supervisors changed how you now view your initial experience in this training activity? For example, how professional storytelling with a senior colleague about a case where mild hypothyroidism was missed due to assuming symptoms were related only to obesity refined your understanding of the critical nature of systematic endocrine evaluation?
How have these experiences impacted upon current practice?
- How has the learning from this initial training activity, in combination with subsequent endocrinology and diabetes experiences, contributed to your overall confidence and competence in systematically investigating metabolic health, particularly in preparing for assessments like Case-based Discussions (CBDs) or Observed Clinical Events (OCEs)? For example, how your accumulated ability in systematically screening for endocrine causes of obesity (e.g., cortisol screening, IGF-1 assessment) now enables you to confidently discuss metabolic health or Cushing’s investigation during a CBD assessment.
- How has reflecting back on this specific training activity, combined with everything you’ve learned since, shaped your current approach to investigating obesity? How does this evolved understanding help you identify when something is beyond your scope of practice or requires escalation? For example, how your evolved approach means you now routinely differentiate between physiological changes due to obesity and genuine pathology (e.g., borderline cortisol results) and seek advice immediately when equivocal dynamic tests for Cushing’s syndrome require complex interpretation, recognising this requires senior consultant review.
- Looking holistically at your training journey, how has this initial endocrine causes of obesity experience, revisited with your current perspective, contributed to your development in meeting the learning outcomes related to performing clinical and laboratory investigation, analysis and management of endocrine disorders and diabetes mellitus? For example, how this foundational experience has supported your development in integrated diagnostic pathways and patient management discussions.
Relevant learning outcomes
| # | Outcome |
|---|---|
| # 1 |
Outcome
Perform clinical and laboratory investigation, analysis and management of endocrine disorders. |
| # 2 |
Outcome
Perform clinical and laboratory investigation, analysis and management of diabetes mellitus. |